Cyclic Helix B Peptide Ameliorates Acute Myocardial Infarction in Mice by Inhibiting Apoptosis and Inflammatory Responses

Cheng Yang,Chao Zhang,Jianguo Jia,Lingyan Wang,Weitao Zhang,Jiawei Li,Ming Xu,Ruiming Rong,Tongyu Zhu
DOI: https://doi.org/10.1038/s41420-019-0161-y
2019-01-01
Cell Death Discovery
Abstract:Cyclic helix B peptide (CHBP) is a peptide derivant of erythropoietin with powerful tissue-protective efficacies in a variety of organ injuries, but without erythropoietic effect. However, the role of CHBP in acute myocardial infarction (AMI) and related mechanisms are not studied yet. In this study, we found in a murine AMI model that the administration of CHBP could ameliorate cardiac injury, increase the survival rate, inhibit cardiomyocyte apoptosis, improve cardiac function and remodeling, and reduce the expression of inflammatory cytokines in the serum and kidney tissue both at 24 h and 8 weeks following AMI. This study suggests that CHBP has the potential to be used as an effective drug in the treatment of AMI.
What problem does this paper attempt to address?